The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice.
Abstract
The thiazolidinediones are novel insulin sensitizers that serve as orally active antidiabetic agents, in rodents, nonhuman primates, and man. We have examined the effects of 4-week oral administration of three thiazolidinediones (AD-5075, BRL 49653, and CS-045) on plasma glucose and triglyceride concentrations in obese hyperglycemic db/db mice. All three agents lower plasma glucose and triglyceride concentrations. Normal levels of glucose are achieved after treatment with AD-5075 (> 1.7 mg/kg) or BRL 49653 (> or = 30 mg/kg), whereas CS-045 (100 or 300 mg/kg) produces only modest reductions in either parameter. Although the thiazolidinediones have demonstrated insulin-sensitizing activities both in vivo and in vitro, their primary molecular target has been unclear. We have compared the in vivo antidiabetic actions described above with the in vitro activities on peroxisomal proliferator-activated receptor-gamma (PPAR gamma). Hamster PPAR gamma 1 was transiently expressed in COS-1 cells to study the binding of [3H]AD-5075. The concentrations of compounds needed to displace radiolabeled AD-5075 from PPAR gamma correlate with their in vivo potency; the Ki values for displacement by cold AD-5075, BRL 49653, and CS-045 are 22, 68, and 1600 nM, respectively. To examine activation of the receptor, it was transiently cotransfected into COS-1 cells with a reporter plasmid containing two copies of a peroxisome proliferator response element. The EC50 values for activation are 2, 6, and 140 nM for AD-5075, BRL 49653, and CS-045, respectively. We have also analyzed limited proteolytic digests of in vitro translated hamster PPAR gamma. The thiazolidinediones produce a conformational change in PPAR gamma analogous to those produced by agonists of other nuclear hormone receptors. In the presence of saturating concentrations of either AD-5075 or BRL 49653, a receptor fragment of 27 kDa is protected from proteolysis by trypsin. These data support the conclusion that the antidiabetic actions of the thiazolidinediones are directly mediated through binding to PPAR gamma and the resulting active conformation of the receptor. Therefore, binding and transactivation assays using PPAR gamma should serve to identify other novel therapeutic agents with potential antidiabetic activities.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Their mode of action involves activation of the peroxisome proliferator-activated receptor (PPARγ), a nuclear transcription factor that is highly expressed in adipose tissue, and the subsequent regulation of genes that are involved in glucose and fat metabolism.356, 357, 358”
From Pancreatic regulation of glucose homeostasis. (2016) · cites this paper as [356]
Citations
Cites
Characterization and expression of a cDNA encoding the human androgen receptor.
Tilley, W. D., Marcelli, M., Wilson, J. D., & McPhaul, M. J. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.1.327 · Cited by 476
Hofmann, C. A., Lorenz, K., Braithwaite, S. S., Colca, J. R., Palazuk, B. J., Hotamışlıgil, G. S., & Spiegelman, B. M. (1994) · Endocrinology · doi:10.1210/endo.134.1.8275942 · Cited by 387
Elbrecht, A., Chen, Y., Cullinan, C. A., Hayes, N. S., Leibowitz, M. D., Moller, D. E., & Berger, J. P. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1044 · Cited by 384
Self-citationVariation in enzymatic transient gene expression assays
Hollon, T. R., & Yoshimura, F. K. (1989) · Analytical Biochemistry · doi:10.1016/0003-2697(89)90616-7 · Cited by 87
Cited by
Sorted by citations
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
Self-citationPancreatic regulation of glucose homeostasis.
Röder, P. V., Wu, B., Liu, Y., & Han, W. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.6 · Cited by 985
Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators
Smith, C. L., & O’Malley, B. W. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0023 · Cited by 931
Galli, A., Crabb, D. W., Ceni, E., Salzano, R., Mello, T., Svegliati–Baroni, G., Ridolfi, F., Trozzi, L., Surrenti, C., & Casini, A. (2002) · Gastroenterology · doi:10.1053/gast.2002.33666 · Cited by 440
Mascaró, C., Acosta, E., Ortiz, J. A., Marrero, P. F., Hegardt, F. G., & Haro, D. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.15.8560 · Cited by 318
Activation of PPARδ alters lipid metabolism in db/db mice
Leibowitz, M. D., Fiévet, C., Hennuyer, N., Peinado-Onsurbe, J., Duez, H., Berger, J., Cullinan, C. A., Sparrow, C. P., Baffic, J., Berger, G. D., et al. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01554-4 · Cited by 308
Self-citationArlt, W., Auchus, R. J., & Miller, W. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100040200 · Cited by 157
Ishida, H., Takizawa, M., Ozawa, S., Nakamichi, Y., Yamaguchi, S., Katsuta, H., Tanaka, T., Maruyama, M., Katahira, H., Yoshimoto, K., et al. (2004) · Metabolism · doi:10.1016/j.metabol.2003.11.021 · Cited by 138
Carley, A. N., Semeniuk, L. M., Shimoni, Y., Aasum, E., Larsen, T. S., Berger, J. P., & Severson, D. L. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00329.2003 · Cited by 94
Self-citationPerfluoroalkyl substances and risk of type II diabetes: A prospective nested case-control study
Donat-Vargas, C., Bergdahl, I. A., Tornevi, A., Wennberg, M., Sommar, J., Kiviranta, H., Koponen, J., Rolandsson, O., & Åkesson, A. (2019) · Environment International · doi:10.1016/j.envint.2018.12.026 · Cited by 88
Peroxisome Proliferator-Activated Receptors and Skin Development
Rosenfield, R. L., Deplewski, D., & Greene, M. E. (2000) · Hormone Research in Paediatrics · doi:10.1159/000053270 · Cited by 69
Effect of Ecdysterone on Glucose Metabolism in vitro
Chen, Q., Xia, Y., & Qiu, Z. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.06.031 · Cited by 51
Metadata
- Authors
- Berger, J., Bailey, P., Biswas, C., Cullinan, C. A., Doebber, T. W., Hayes, N. S., Saperstein, R., Smith, R. G., & Leibowitz, M. D.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 1996-10
- Volume
- 137
- Issue
- 10
- Pages
- 4189-4195
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2030207960
- Cited by
- 391
- References
- 4
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 3 · 2021: 6 · 2019: 4 · 2018: 5 · 2017: 3 · 2016: 5 · 2015: 14 · 2014: 4 · 2013: 11 · 2012: 11
- FWCI
- 7.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- thiazolidinediones, PPARγ, insulin sensitizers, antidiabetic drugs, receptor conformational change, ligand binding, receptor activation, peroxisome proliferator response element, hyperglycemia, hypertriglyceridemia, obesity, db/db mice, nuclear receptors, limited proteolysis
- MeSH terms
- Animals, Blood Glucose, Diabetes Mellitus, Cricetinae, Hyperglycemia, Insulin Resistance, Male, Molecular Conformation, Peptide Hydrolases, Thiazoles, Transcription Factors, Triglycerides, Hypertriglyceridemia, Receptors, Cytoplasmic and Nuclear, COS Cells, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
